bioshares report

Excellent summary. Especially good to hear that CZD's technology has several advantages over current widely used techniques.

'Showing that the NovoSorb biodegradable material can be successfully incorporated into a wound for treatment is a major advance for Calzada. Greenwood suggested the technology is very close to entering a paradigm shift in the field of wound treatment. With the results achieved this year, we expect this stock will start to receive increased attention from investors.'

Very odd that the SP has not reflected this significant advance ?